HC Wainwright Has Bearish Outlook for Omeros FY2026 Earnings

Omeros Corporation (NASDAQ:OMER) – Investment analysts at HC Wainwright lowered their FY2026 EPS estimates for shares of Omeros in a research note issued on Thursday, January 8th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will earn ($2.30) per share for the year, down from their previous forecast of ($1.77). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros’ FY2027 earnings at ($0.51) EPS, FY2028 earnings at $2.35 EPS and FY2029 earnings at $5.13 EPS.

Several other research analysts have also commented on the stock. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday. D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. Finally, WBB Securities reiterated a “strong-buy” rating and issued a $45.00 price target on shares of Omeros in a research report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

Omeros Stock Down 7.1%

NASDAQ:OMER opened at $12.49 on Monday. The stock’s fifty day moving average is $10.58 and its two-hundred day moving average is $6.68. Omeros has a 52 week low of $2.95 and a 52 week high of $17.65. The stock has a market capitalization of $885.54 million, a price-to-earnings ratio of -6.18 and a beta of 2.38.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.39.

Institutional Trading of Omeros

Several institutional investors have recently added to or reduced their stakes in OMER. Vanguard Group Inc. lifted its stake in Omeros by 1.9% during the third quarter. Vanguard Group Inc. now owns 3,346,958 shares of the biopharmaceutical company’s stock worth $13,723,000 after purchasing an additional 63,381 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Omeros by 39.3% in the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after buying an additional 263,095 shares during the period. Marshall Wace LLP raised its position in Omeros by 15.1% during the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock valued at $2,224,000 after buying an additional 97,224 shares during the period. Bank of Montreal Can increased its stake in shares of Omeros by 1.4% in the second quarter. Bank of Montreal Can now owns 571,095 shares of the biopharmaceutical company’s stock worth $1,713,000 after acquiring an additional 8,000 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Omeros by 1,201.1% during the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after acquiring an additional 384,168 shares in the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: HC Wainwright sharply raised its price target to $40 and kept a Buy rating, highlighting large upside vs. the current share level — this upgrade is a clear bullish catalyst. HC Wainwright PT raise
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating with a $36 price target, providing additional analyst support for upside. D. Boral Capital reaffirmation
• Positive Sentiment: Omeros announced pricing for YARTEMLEA at $36,000 per single‑dose vial — a premium price that boosts near‑term revenue potential for its recently approved transplant complication therapy. Reuters: pricing
• Positive Sentiment: Company comments on FDA approval and commercialization plans for YARTEMLEA underline management’s readiness to commercialize and support uptake, which can validate the higher price target narratives. Seeking Alpha transcript
• Neutral Sentiment: HC Wainwright published detailed near‑term EPS forecasts (Q1–Q4 2026 showing losses) while projecting a large turnaround by FY2030 (EPS $6.69); this signals long‑term optimism but acknowledges multi‑year losses.
• Neutral Sentiment: Needham reiterated a Hold rating, reflecting balanced risk/reward as YARTEMLEA ramps. Needham Hold note
• Neutral Sentiment: There was a reported after‑hours bounce recently, indicating volatile trading around the approval/pricing news rather than steady directional conviction. MSN after‑hours
• Negative Sentiment: Near‑term financials remain loss‑making (consensus and HC Wainwright 2026 EPS estimates are negative), which can pressure the stock until commercial execution and revenue ramp are proven.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.